Fundraising FoxNextech Invest — 2019 Investments
4 investments dated 2019 · listed companies and verified rows first · show all
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)inDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesHBM Healthcare InvestmentsHBM PartnersOUP (Osage University Partners)+2 more
Diamond Therapeutics is a preclinical biotechnology company developing drug treatments for psychiatric and neurological disorders, with a focus on the pharmacology and therapeutic use of psychedelic compounds.
BiotechHealthtechMental HealthToronto, CA
Judy Blumstock(Chief Executive Officer, Founder, Director)inMichael B. McDonnell(Chief Medical Officer)inGrant McCutcheon(Chief Financial Officer)in
Co-investorsJLSNoeticPalo Santo VCNew Enterprise Associates (NEA)RA Capital
BiotechSan Diego, US
Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)
BoardBret Zbar(Director)Carl Gordon(Director)Michael Rome(Director)in
Co-investorsForesite CapitalViking GlobalJanus Henderson InvestorsRA CapitalVenrock Healthcare Capital PartnersViking Global Investors
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.